William J Burlingham, PhD
- Division of Transplantation
600 Highland Ave
Madison, WI 53792-3284
- PhD, Biology, Syracuse University, Syracuse, NY, 1979
- Postdoctoral Research Fellowship, National Cancer Institute, Mayo Clinic and Mayo Medical School, Rochester, MN, 1980-1983
Dr. Burlingham has developed a highly respected transplant basic research program that focuses on acquired immunologic tolerance. His laboratory hopes to gain insight into graft acceptance by studying transplant recipients who have survived after stopping immunosuppressive drugs.
Specifically, his research focuses on the natural exchange of soluble antigens and low numbers of white blood cells that occurs between mother and child during pregnancy and nursing. The lab’s working hypothesis is that this exchange, which leads to persistence of bone marrow-derived maternal blood cells within the offspring (“microchimerism”) may induce a “natural” form of tolerance. This tolerance, if harnessed, may allow for drug-free acceptance of transplanted grafts. Such natural tolerance has recently been shown to be the result, not of having microchimerism per se, but having a specific type of rare maternal cells capable of producing exosomes– tiny virus-like vesicles composed of lipid, protein, and nucleic acids. The goal is now to investigate how these intercellular messengers modify the host antigen presenting cells, and T cells during tolerance, with a view toward therapeutic applications.
The other major focus of Dr. Burlingham’s lab is the phenomenon of autoimmunity that develops after lung transplantation. A novel type of T Cells, called Th-17, react to collagen type V and cause inflammation and over-production of collagens causing airway blockage and graft loss. His lab is working on ways to inhibit this process by new forms of immune suppressive drugs and by increasing T regulatory cells that normally prevent autoimmune disease.
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS, Tang Q, Guinan EC, Battaglia M, Burlingham WJ, Roberts ISD, Streitz M, Josien R, Böger CA, Scottà C, Markmann JF, Hester JL, Juerchott K, Braudeau C, James B, Contreras-Ruiz L, van der Net JB, Bergler T, Caldara R, Petchey W, Edinger M, Dupas N, Kapinsky M, Mutzbauer I, Otto NM, Öllinger R, Hernandez-Fuentes MP, Issa F, Ahrens N, Meyenberg C, Karitzky S, Kunzendorf U, Knechtle SJ, Grinyó J, Morris PJ, Brent L, Bushell A, Turka LA, Bluestone JA, Lechler RI, Schlitt HJ, Cuturi MC, Schlickeiser S, Friend PJ, Miloud T, Scheffold A, Secchi A, Crisalli K, Kang SM, Hilton R, Banas B, Blancho G, Volk HD, Lombardi G, Wood KJ, Geissler EK
Lancet 2020 05 23; 395(10237): 1627-1639
[PubMed ID: 32446407]
Treg-Cell-Derived IL-35-Coated Extracellular Vesicles Promote Infectious Tolerance.
Sullivan JA, Tomita Y, Jankowska-Gan E, Lema DA, Arvedson MP, Nair A, Bracamonte-Baran W, Zhou Y, Meyer KK, Zhong W, Sawant DV, Szymczak-Workman AL, Zhang Q, Workman CJ, Hong S, Vignali DAA, Burlingham WJ
Cell Rep 2020 01 28; 30(4): 1039-1051.e5
[PubMed ID: 31995748]
Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients.
Hennes AJ, Holdener KE, Burlingham WJ, Mandelbrot DA, Parajuli S, Mohamed MA, Garg N, Aziz F, Astor BC, Djamali A
Transplant Direct 2020 Feb; 6(2): e526
[PubMed ID: 32095512]
Role of exosomes in tumour and transplant immune regulation.
Lema DA, Burlingham WJ
Scand. J. Immunol. 2019 Nov; 90(5): e12807
[PubMed ID: 31282004]
Epigenetic Priming of Human Pluripotent Stem Cell-Derived Cardiac Progenitor Cells Accelerates Cardiomyocyte Maturation.
Biermann M, Cai W, Lang D, Hermsen J, Profio L, Zhou Y, Czirok A, Isai DG, Napiwocki BN, Rodriguez AM, Brown ME, Woon MT, Shao A, Han T, Park D, Hacker TA, Crone WC, Burlingham WJ, Glukhov AV, Ge Y, Kamp TJ
Stem Cells 2019 07; 37(7): 910-923
[PubMed ID: 31087611]